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http:WHAT THIS PAPER ADDS
Stabilization of aneurysmal growth using mesenchymal stem cells in an already-formed abdominal aortic
aneurysm model has not been published. Direct cellular seeding using catheter-based procedures could be an
alternative to treat aortic expansion associated with type II endoleak after endovascular aortic aneurysm repair.Purpose: Abdominal aortic aneurysms (AAAs) expand because of aortic wall destruction. Enrichment in Vascular
Smooth Muscle Cells (VSMCs) stabilizes expanding AAAs in rats. Mesenchymal Stem Cells (MSCs) can
differentiate into VSMCs. We have tested the hypothesis that bone marrow-derived MSCs (BM-MSCs) stabilizes
AAAs in a rat model.
Material and methods: Rat Fischer 344 BM-MSCs were isolated by plastic adhesion and seeded endovascularly in
experimental AAAs using xenograft obtained from guinea pig. Culture medium without cells was used as control
group. The main criteria was the variation of the aortic diameter at one week and four weeks. We evaluated the
impact of cells seeding on inﬂammatory response by immunohistochemistry combined with RT-PCR on MMP9
and TIMP1 at one week. We evaluated the healing process by immunohistochemistry at 4 weeks.
Results: The endovascular seeding of BM-MSCs decreased AAA diameter expansion more powerfully than VSMCs
or culture medium infusion (6.5%  9.7, 25.5%  17.2 and 53.4%  14.4; p ¼ .007, respectively). This result was
sustained at 4 weeks. BM-MSCs decreased expression of MMP-9 and inﬁltration by macrophages (4.7  2.3 vs.
14.6  6.4 mm2 respectively; p ¼ .015), increased Tissue Inhibitor Metallo Proteinase-1 (TIMP-1), compared to
culture medium infusion. BM-MSCs induced formation of a neo-aortic tissue rich in SM-alpha active positive cells
(22.2  2.7 vs. 115.6  30.4 cells/surface units, p ¼ .007) surrounded by a dense collagen and elastin network
covered by luminal endothelial cells.
Conclusions: We have shown in this rat model of AAA that BM-MSCs exert a specialized function in arterial
regeneration that transcends that of mature mesenchymal cells. Our observation identiﬁes a population of cells
easy to isolate and to expand for therapeutic interventions based on catheter-driven cell therapy.
 2013 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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//dx.doi.org/10.1016/j.ejvs.2013.03.007cells (VSMCs), and absence of compensatory aortic recon-
struction.1,2 In expanding experimental AAAs, correction of
depletion in VSMCs triggers wall reconstruction and stabi-
lizes the diameter of the diseased aorta.3e5 Accordingly,
increasing VSMC content by endovascular cell seeding could
be a therapeutic strategy. It requires the identiﬁcation of
cells easy to isolate and to expand.
A subset of bone marrow (BM) cells, referred to as
Mesenchymal Stem Cells (MSCs) can be isolated by adherence
to plastic wells and can easily be expanded.6 As MSCs are
multipotent and can home at sites of injury, it has been
F. Schneider et al. 667proposed that BM-MSCs contribute to post-natal tissue
repair.7 In vitro, MSCs have been shown to differentiate into
VSMC-like cells upon PDGF-BB stimulation.8 In vivo,MSCs have
been shown to contribute to healing of mechanically injured
arteries.9 This repair process results in intimal hyperplasia,
a VSMC-rich tissue hypertrophy that contrasts with the VSMC-
deprived atrophy of the aneurysmal wall. Previous reports
have suggested that MSCs may be of interest in AAAs.10
However, there is no demonstration that MSCs stabilize
expanding AAAs. This demonstration requires a model of AAA
with statistically signiﬁcant diameter expansion after cell
seeding, with thrombus at wall/blood interface.3,4 The xeno-
graft model, in which aneurysmal degeneration is driven by
inﬂammation, matrix metalloprotease activity regulated by
the plasmin pathway,11,12 fulﬁlls these requirements.
In this study, we have tested the hypothesis that local
endovascular seeding of BM-MSCs induces aortic tissue
growth and stabilizes the diameter of expanding experi-
mental AAAs, a strategy compatible with future catheter-
based cell therapy approaches in aortic aneurysm disease.MATERIAL AND METHODS
BM-MSC isolation
Cells were isolated from 12 week old male Fischer 344 rats
(Charles River, St Quentin Fallavier, France). Aortic VSMCswere
isolated5 and grown in RPMI 1640 andMedium 199 (1:1), with
L-glutamine and 10% fetal calf serum (FCS) (Invitrogen,
Corporation, Paisley, UK). BM-MSCs were isolated from femurs
and tibias by centrifugation and selected by plastic adhesion
after overnight incubation in a-MEM with 20% FCS. After this
step, medium was removed after 72 h. Antibiotics and anti-
fungic were added in each culture medium. Adherent cells
were passaged when reaching 80% conﬂuence. BM-MSCs
phenotypes were shown to express MSC markers (CD44,
CD73, CD90, CD105), but not leukocytemarkers (CD45, CD11b).Surgery
Animals were housed and taken care of according to the
European Union Standards. They received analgesia and were
anesthetized with .1 ml/100 g body weight pentobarbital i.p.
AAAs were generated in 250 g-12 week old, male Fischer 344
rats by implanting a segment of Hartley guinea pig aorta
(xenograft) as previously described.3 Guinea pig (Charles
River) infrarenal aortas were decellularized using .1% sodium
dodecyl sulfate (Sigma, St-Louis, USA) to obtain intact tubes of
aortic ECMwhich were orthotopically implanted into rats with
10-0 sutures. Fourteen days after xenograft implantation,
a chimeric AAA (>50%diameter increase) haddeveloped from
the degraded guinea pig ECM inﬁltrated by cells from rat, with
a luminal thrombus,3 as previously described. AAAs were
isolated fromblood ﬂowby clamps.The lumenwas rinsedwith
culture medium through a PE10 catheter introduced by an
aortotomy performed downstream in the native aorta.
Passage 5 to 6 BM-MSCs (n¼ 6 for the time point at one week
and n¼ 5 for the timepoint at onemonth) or VSMCs (n¼ 5 for
a unique time point at one week) suspended in culturemediumwith 5% FCS were injected into the AAA as previously
described.3 To summarize, animals were perfused 2 min on
each side, so perfusion took 8 min. In another set of experi-
ments BM-MSCs were stained before seeding with the ﬂuo-
rescent dye PKH26 (Sigma).These xenograft were harvested at
48 h and one week to get sufﬁcient ﬂuorescent signal. As
controls, AAAswere infused with culturemediumwith 5% FCS
with no cell (n ¼ 5 at one week and n ¼ 5 at one month).
AAA assessment
AAA maximum transverse diameter was measured at endo-
vascular infusion and before euthanasia 1 or 4 weeks later
using a graduated scale under dissecting microscopy.
Percentage of diameter increase was calculated as follows:
(diameter at evaluation time  diameter at seeding)  100/
diameter at seeding. After inclusion into parafﬁn, 5 mm cross
sections were generated from the center of AAAs. Elastin and
collagen were stained by orcein and sirius red, respectively.
For immunohistochemistry, primary antibodies were mouse
anti ratmonoclonals: ED1 clone formonocytes/macrophages,
RECA for endothelial cells (Serotec, Oxford, England) and
smooth muscle alpha-actin (clone 1A4, Sigma). An alkaline
phosphataseeantialkaline phosphatase technique was used
(Dakopatts). Control sections were generated by omission of
the primary antibody and with a nonrelevant primary anti-
body. Quantitative analyses used Image-Pro Plus Software
(Media, Cybernetics, Bethesda, Md). Two blinded observers
recorded the percentage of the total area for each section.
mRNA semi-quantiﬁcation
MMP-9 and TIMP-1 mRNA contents were analyzed using
reverse transcription polymerase chain reaction (RT-PCR),
comparative to the domestic gene 18S (QuantumRNA18s
Internal Standards kit, Ambion,Montrouge, France) (primers:
MMP-9: forward: 50-CTGCGTATTTCCATTCATCTT-30; reverse:
50-ATGCCTTTTATGTCGTCTTCA-30; TIMP-1: forward: 50-
CCCCAGAAATCAACGAGAGACCA-30; reverse: 50-ACACCCCA-
CAGCCAGCACTAT-30). Intima, andmedia plus adventitia were
separated by micro dissection and pooled by layers and
groups. Total RNA was extracted with TRIzol(Life Technol-
ogies, Paisley, UK) and treated with grade I DNase (Roche
Molecular Biomedicals, Rosny, France). Reverse transcription
was donewith randomprimers, and Reverse transcriptaseM-
MLV, dNTP, dithiothreitol, and ribonuclease inhibitor (Euro-
bio, Les Ulis, France). PCR was performed in a PCR Express
thermo cycler (Hybaid, UK) with DNA Taq polymerase
(Eurobio, Les Ulis, France). Bands of ampliﬁed sequences
corresponding to the gene of interest and to 18s were
quantiﬁed with Gel Analysis (Iconix, Marnes La Coquette,
France). Results were expressed as ratios between signals
corresponding to the gene of interest and 18s.
Statistical analysis
Results were expressed as mean  SD. For independent
qualitative parameters a Chi-square test was used (biostat
TGV). The nonparametric ManneWhitney U and Kruskal
Wallis tests (Statview, version 4.5) were used for statistical
668 European Journal of Vascular and Endovascular Surgery Volume 45 Issue 6 June/2013comparisons between two and three groups, respectively.
P < .05 was considered signiﬁcant.
RESULTS
Endovascular seeding of BM-MSCs stabilizes the diameter
of expanding AAAs
BM-MSCs isolated by plastic adhesion were seeded onto the
lumen of formed and expanding AAAs with luminal thrombus.
On cross sections made from AAAs harvested 48 h (n¼ 2) and
one week after seeding (n ¼ 2), fusion images showed co-
localization of nuclei stained with DAPI and red ﬂuorescence
in the intermediate area of the intima, indicating presence of
seeded MSCs or daughter cells (Fig. 1). No PKH26 labeling
could be seen four weeks after BM-MSC seeding.
One million BM-MSCs were seeded onto the lumen of
already formed AAAs. In the control group infused with
culture medium with no cell, the diameter of AAAs
continued to increase at one week (n ¼ 5, 48.2  17.0%)
and at four weeks (n ¼ 5, 88.3  61.6%) after cell infusion.
In contrast, endovascular injection of one million BM-MSCs
stopped AAA diameter expansion at one (n ¼ 6, 6.6  9.7%)
and at four weeks (n ¼ 5, 9.2  30.1%). Statistical analysis
shown that one and four week growth rate differences
between control and BM-MSC groups were signiﬁcant
(p ¼ .006 and p ¼ .028 respectively) (Fig. 2).
BM-MSCs decrease inﬂammation and further MMP-driven
wall destruction, and trigger tissue regeneration in formed
AAAs
Addition of MSCs decreased inﬁltration of AAAs by mono-
cyte/macrophages at one week (ED1 positive cells:
14.6  6.4 vs. 4.7  2.3/mm2 in control and BM-MSC
groups, respectively, p ¼ .015) (Fig. 3A). Semi-quantitative
analysis by RT-PCR expression in AAAs over the domestic
gene 18s showed a decrease in MMP-9, and an increase in
TIMP-1, mRNAs, one week after endovascular injection ofFigure 1. Cross-sectional views of rat AAAs one week after endovascular
nuclear staining with DAPI; c: PKH26-labeling; b: fusion of a and c; d: h
PKH26 staining (red). e: Hematoxylin-Eosin staining of section cut. OriginaBM-MSCs, with different expression patterns according to
localization in thrombus-intima or media-adventitia (Fig. 3B)
(n ¼ 3). Immunostaining with an anti-MMP-9 antibody
conﬁrmed a sharp decrease in MMP-9 protein accumulation
upon MSC endovascular seeding.
Four weeks after BM-MSC seeding, collagen content,
expressed as the percentage of total vessel wall area, and
elastin content, expressed as the percentage of medial area,
were signiﬁcantly higher than in controls (collagen: 7.35 1.9
vs. 22.5  9.1 Surface-%, p ¼ .007; elastin: 4.25  4.30 vs.
28.52  16.5 Surface-%, p ¼ .008) (Fig. 4a, b, d, e).
After BM-MSC seeding, a tissue developed on the
luminal aspect of AAAs and replaced the thrombus which
persisted in the control group (Fig. 4aef). Cell and extra-
cellular matrix accumulating on the luminal surface of the
aneurismal wall recapitulated the organization of an aortic
wall. The neo aortic wall contained a dense extracellular
network with collagen (Fig. 4a, d) and elastin (1.42  .9 vs.
6.6  1.9 Surface-%, p ¼ .007, in control and BM-MSC
groups, respectively, p ¼ .007) (Fig. 4b, e). The neo vessel
wall contained abundant SM-alpha-active positive cells
(22.2  2.7 vs. 115.6  30.4 cells/surface units, in control
and MSC groups, respectively, p ¼ .007) (Fig. 4c, f). Surface
units were calculated by measurement of media’s surface.
Rat Endothelial Cell Antigen (RECA) immunostaining
showed endothelial cells covering VSMC-like cells at the
interface with circulating blood. In contrast the luminal
surface of the AAAs infused with culture medium was
covered with thrombus devoid of endothelium (Fig. 4g, h).
Rat BM-MSCs stabilize expanding AAAs more efﬁciently
than VSMCs
After having shown previously that aortic VSMCs stabilize
expanding rat AAAs,3 we designed a doseeresponse
experiment to compare the impact of BM-MSC and VSMC
seeding on this clinically relevant parameter at one week.
Whereas ﬁve million VSMCs were needed to curb diameterseeding of PKH26 labeled MSCs. Luminal side is indicated by (*). a:
igh power ﬁeld view of b. Nuclear staining (/) is co-localized with
l magniﬁcation: a, b, c, e:20; d:100.Thr: thrombus.Med:media.
Figure 2. A. Diameter expansion of formed AAAs. Y axis is diameter increase (%). B: Macroscopic view of xenograft 28 days after culture
medium perfusion as controls (upper panel) and MSCs perfusion (lower panel). The dotted green line indicate the exact site of outer to
outer wall diameter measurement. Standard deviation is indicated by bar errors.
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stabilize AAA diameter (Fig. 5). The mean diameter expan-
sion rate was 48.2  17.0% after culture medium infusion
(controls), 25.5  17.2% after VSMC seeding (p ¼ .11 in
comparison with controls) and 6.6  9.7% after MSC infu-
sion (p ¼ .006 in comparison with controls) (Kruskalle
Wallis test between the three groups: p ¼ .007).Figure 3. A: Representative view of immunohistochemistry against E
mRNAs encoding for MMP-9 and TIMP-1 in AAA extracts one week a
deviation is indicated by bar errors.DISCUSSION
Using a rat model of formed, expanding, AAAs with
a luminal thrombus, we demonstrate that the endovascular
seeding of BM-MSCs down-regulates inﬂammation and
proteolysis, triggers aortic regeneration and stops diameter
expansion. In this setting, BM-MSCs appear to be more
efﬁcient than aortic VSMCs in stabilizing formed AAAs. OurD-1 (original magniﬁcation: 4). B: Semi-quantitative RT-PCR of
fter endovascular infusion, over the domestic gene 18s. Standard
Figure 4. Representative cross-sectional views of AAAs four weeks after endovascular treatment. Upper panel: control group (a, b, c, g);
lower panel: MSC treated AAA (d, e, f, h). a, d: Sirius red; b, e: orcein; c, f: anti-smooth muscle alpha-actin immunostatining. Orginal
magniﬁcation: 4. Thr: luminal thrombus; Ih: intimal hyperplasia. g, h: immunostaining of rat endothelial cells (arrow: endothelium lining
on the luminal aspect; Lu: lumen), original magniﬁcation 40.
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unique tissue healing properties that could be utilized to
gain stability of VSMC-deprived AAAs.
AAAs expand inexorably once they have reached 40 mm in
diameter,13 a suggestion that no efﬁcient repair occurs in
these aortic lesions. Healing of injured arteries usually occurs
on their luminal aspect, resulting in cell and ECM accumu-
lation resulting with an increase of the artery wall mass. Cells
contributing to this repair process may be VSMCs, blood-
derived MSCs or medial and adventitial14 progenitors15
converging toward the luminal aspect covered with ﬁbrin
and platelets.10 In human AAAs and in the xenograft model,
this luminal repair does not occur. In particular, signiﬁcant
intimal hyperplasia does not develop. As an explanation for
this absence of endoluminal healing, it can be proposed that
the migration of repair cells through the aneurysmal wall
toward the intima faces limiting factors, such as
inﬂammation-driven apoptosis16 and ECM disorganization.17
We have observed elsewhere that the luminal surface of the
thrombus in human AAAs encloses factors instrumental for
MSC recruitment, platelet-derived growth factors, andFigure 5. Doseeresponse experiment comparing a single quantity
of seeded MSCs with increasing quantities of VSMCs one week
after perfusion. Standard deviation is indicated by bar errors.MSC-like cells, a suggestion that healing aborts on the
luminal aspect of AAAs. To support this hypothesis, other
have shown that MSCs do not expand in contact with human
AAA thrombus, due to polymorphonuclear cells-derived
proteases.18 The lumen of AAAs in the xenograft model is
covered by a luminal thrombus3e5 with polymorphonuclears,
a recapitulation of a structural feature important for the
evolution of human AAAs.19 We have documented in this
study, using PKH26 labeling, that the addition of an important
quantity of BM-MSCs resulted in cell attachment and survival
up to one week after endovascular seeding.
The expansion and rupture of AAAs in the xenograft
model occur after aortic ECM injury by inﬂammation and
MMP-driven proteolysis.11,12 We have shown that endo-
vascular addition of BM-MSCs down-regulates monocyte/
macrophage accumulation, and decreases the MMP
proteolytic burden in the wall of formed AAAs. These results
are in line with other studies showing that MSCs control
inﬂammation in host tissues.20 BM-MSCs addition stopped
aneurysmal wall injury presumably through paracrine
secretion of protease inhibitors as suggested by TIMP-1
mRNA accumulation at sites of BM-MSC seeding in our
in vivo experiments.3 In a report on MSC peri-adventitial
seeding in an ApoE-Angiotensin II model, Hashizume et al.
have observed that prevention of AAA degeneration and
preservation of medial elastin was associated with an
increased expression of IGF-1 and TIMP-1.10
Another important ﬁnding of this study was that endo-
vascular seeding of BM-MSCs resulted in the formation of
a structured arterial tissue in the intima in replacement of
the luminal thrombus, a validation of our hypothesis that
BM-MSCs induce aortic healing in the context of AAAs and
increase wall mass. An endothelium separated VSMC-like
cells from blood, contrasting with the surface of the
F. Schneider et al. 671luminal thrombus in control AAAs as well as in human
atherosclerotic AAAs, devoid of endothelium. BM-MSC
seeding was followed by the accumulation of SM-alpha
actin-positive cells surrounded by ECM with collagen and
elastin, a recapitulation of artery wall structure. These data
are concordant with other data demonstrating production
of ECM by MSCs.21 BM-MSC seeding was followed by
generation of elastin in the intimal outgrowth, which has
not been observed after VSMC seeding.3 Elastin is a highly
specialized molecule that determines important mechanical
properties in arteries.22 It is generally accepted that provi-
sional elastin is produced by VSMCs in the artery wall
during ontogeny. Our present observations suggest that in
arterial repair, progenitor cells induce the generation of
a more specialized tissue than differentiated VSMCs. In
order to compare BM-MSCs and VSMCs in their ability to
stabilize expanding AAAs, we have designed a dosee
response experiment. Five fold less BM-MSCs than VSMCs
were needed to gain diameter stabilization. Further inves-
tigations are needed to unravel mechanisms by which
undifferentiated BM-MSCs perform better than VSMCs in
stabilizing AAAs. Importantly, neither BM-MSC nor VSMC3
addition triggered repair of ECM in the media layer of
AAAs. The absence of PKH-labeled cells in the AAA wall itself
demonstrates that BM-MSCs did not penetrate into the
injured vessel wall. Direct differentiation of MSCs into SM-
like cells has been suggested in previous experiments in
which MSCs were seeded on vascular prostheses.20
However, accumulating data suggest that healing elicited
by MSCs in injured tissues involves paracrine mechanisms
rather than direct differentiation and incorporation of
progenitors in scar tissues.23
Previous attemps to regenerate tissues in the cardiovas-
cular system have been limited by the poor survival of MSCs
after seeding.24e26 In our experiments, survival of BM-MSCs
documented by PKH labeling might have been facilitated by
direct contact of seeded cells with circulating blood. A
previous work has already shown promising results to
stabilize the growth of an AAA model in pig by peri
adventitial MSCs application.27 This ﬁnding, together with
the development of catheter-based technologies in current
vascular interventions, suggests that endovascular, rather
than peri-aortic delivery, offers perspectives for an
appealing clinical transfer of technology. The most valuable
clinical application could be BM MSCs seeding to treat
aortic expansion secondary to type II endoleak. BM-MSCs
could be easily isolated and expanded in vitro from
a patient after bone marrow harvesting. These cells could
be injected as an autograft process in the space between
the native aortic wall and the stent graft through feeding
inferior mesenteric artery catheterism, or direct sac punc-
ture guided by computerized tomography.CONCLUSIONS
We have demonstrated in this study that BM-MSCs exert
a specialized function in arterial regeneration and functional
recovery that transcends mature mesenchymal cells.Endovascular seeding of BM-MSCs induces accumulation of
aortic tissue and stabilizes the diameter of expanding AAAs.
This ﬁnding opens a new ﬁeld for therapeutic intervention
based on catheter-driven cell therapy.FUNDING
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